2019
Chapter 12 Medications for the Treatment of Type II Diabetes
Van Name M. Chapter 12 Medications for the Treatment of Type II Diabetes. 2019, 101-106. DOI: 10.1016/b978-0-323-55138-0.00012-7.Chapters
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use